Details of the Drug Reposition

General Information of This Drug (ID: DM92AH3)

Drug Name
Cyproheptadine   DM92AH3
Synonyms
Ciproheptadina; Ciprovit; Cypoheptadine; Cyproheptadiene; Cyproheptadinum; Dihexazin; Dronactin; Eiproheptadine; Periactin; Periactine; Periactinol; Viternum; Cyproheptadine Hcl; MK 141; Ciproheptadina [INN-Spanish]; Ciprovit (TN); Cyproheptadine (INN); Cyproheptadine [INN:BAN]; Cyproheptadinum [INN-Latin]; Dibenzosuberonone/Cyproheptadine; Periactin (TN); 1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine; 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine; 4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene; 4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine; 4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine; 5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
Therapeutic Class
Antihistamines
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
6 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Leukemia DISNAKFL N.A. Approved [1]
Malnutrition DIS1UUNY 5B50-5B71 Approved [1]
Allergic rhinitis DIS3U9HN CA08.0 Approved [1]
Urticaria DIS9WQAI EB00-EB05 Approved [1]
Rhinitis DISKLMN7 FA20 Approved [2]
Weight gain DISDJU1H MG43.6 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 Indications(s)
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Allergic conjunctivitis DISZ5ZJN 9A60.02 Withdrawn [3]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Pruritus DISVH62W EC90 Investigative [1]
------------------------------------------------------------------------------------

References

1 Cyproheptadine FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling